Apellis Pharmaceuticals APLS has been analyzed by 15 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 4 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 2 | 1 | 1 | 0 | 0 |
| 2M Ago | 1 | 2 | 1 | 0 | 0 |
| 3M Ago | 4 | 1 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Apellis Pharmaceuticals, revealing an average target of $79.4, a high estimate of $106.00, and a low estimate of $60.00. This current average reflects an increase of 18.51% from the previous average price target of $67.00.
Interpreting Analyst Ratings: A Closer Look
A clear picture of Apellis Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Graig Suvannavejh | Mizuho | Maintains | Neutral | $60.00 | $60.00 |
| Anupam Rama | JP Morgan | Raises | Overweight | $79.00 | $78.00 |
| Eliana Merle | UBS | Raises | Buy | $89.00 | $87.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $92.00 | - |
| Laura Chico | Wedbush | Raises | Neutral | $67.00 | $60.00 |
| Graig Suvannavejh | Mizuho | Raises | Neutral | $60.00 | $49.00 |
| Colleen Kusy | Baird | Maintains | Outperform | $81.00 | - |
| Akash Tewari | Jefferies | Raises | Buy | $80.00 | $68.00 |
| Justin Kim | Oppenheimer | Raises | Outperform | $79.00 | $75.00 |
| Joseph Stringer | Needham | Raises | Buy | $75.00 | $70.00 |
| Colleen Kusy | Baird | Raises | Outperform | $81.00 | $71.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $92.00 | $82.00 |
| Laura Chico | Wedbush | Raises | Neutral | $60.00 | $39.00 |
| Steven Seedhouse | Raymond James | Raises | Strong Buy | $106.00 | $67.00 |
| Salveen Richter | Goldman Sachs | Raises | Buy | $90.00 | $65.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Apellis Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Capture valuable insights into Apellis Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Apellis Pharmaceuticals analyst ratings.
Discovering Apellis Pharmaceuticals: A Closer Look
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Understanding the Numbers: Apellis Pharmaceuticals's Finances
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Apellis Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 545.89%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -60.51%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -41.51%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -11.02%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.57, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
